Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

Pharmaceuticals : Displaying 14-23 of 33


GlaxoSmithKline Alleged to Pay Bribes in China
by Pratap ChatterjeeCorpWatch Blog
July 15th, 2013
GlaxoSmithKline (GSK) has been accused of bribing doctors in China in order to boost sales. Chinese government officials say they have uncovered evidence of a bribery scheme involving 700 travel agencies who were used to funnel as much as three billion yuan ($480 million) in payments.

Myriad Loses Patent to Breast Cancer Genetic Test
by Richard SmallteacherCorpWatch Blog
June 13th, 2013
Myriad Genetics has lost its right to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer. The American Civil Liberties Union (ACLU), which sued the company, claimed that the patent would limit scientific research as well as health care options for women.

Ranbaxy Pays $500 Million Fine for Selling Bad Batches of Generic Medicines
by Pratap ChatterjeeCorpWatch Blog
May 14th, 2013
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India. The settlement comes 16 months after the company signed an agreement with U.S. authorities to change its ways.

Medical Trial Data Activists Score Win Over Glaxo
by Pratap ChatterjeeCorpWatch Blog
February 7th, 2013
All data on completed medical experiments are to be made available to the general public by GlaxoSmithKline, the biggest UK pharmaceutical company. The announcement is a major win for the AllTrials campaign mounted by healthcare activists as well as researchers that has gathered widespread support.

UK Pathology Labs Suffer In Quality Under Serco Management
by Puck LoCorpWatch Blog
October 24th, 2012
Privatization of major medical laboratories from the National Hospital Service (NHS) in Britain has led to a dramatic decline in service quality, according to a “Transforming Pathology, the Serco way,” a recent report from UK-based researchers Corporate Watch.

Indian Supreme Court to Hear Novartis “Patents Versus Patients” Case
by Pratap ChatterjeeCorpWatch Blog
August 21st, 2012
Novartis, the Swiss pharmaceutical company, will appear before the Indian Supreme Court Wednesday to appeal against a patent rejection for a popular cancer drug. A decision in favor of the company could have a devastating impact on cheap supplies of many kinds of generic drugs for poor patients.

Pfizer Admits Bribery in Eight Countries
by Pratap ChatterjeeCorpWatch Blog
August 8th, 2012
Pharmaceutical giant Pfizer has agreed to pay a total of $60.2 million in penalties to U.S. government regulators to settle documented charges of bribery in eight countries: Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and Serbia.

Court to Hear Challenge to Myriad’s Human Gene Patent
by Pratap ChatterjeeCorpWatch Blog
July 19th, 2012
Should a private company be allowed to patent isolated human genes? A lawsuit to be heard Friday pits Myriad Genetics of Utah against the American Civil Liberties Union (ACLU). Myriad wants to be the exclusive U.S. commercial provider of genetic screening tests for breast cancer or ovarian cancer.

Fake Drug Plague or Pharmaceutical Industry Attack on Generics?
by Pratap ChatterjeeCorpWatch Blog
June 13th, 2012
Are Africa and South East Asia just suffering from a deluge of fake medicines that is causing disease resistance to rise? Or are they also suffering from a deluge of poorly informed media articles, encouraged by the pharmaceutical industry that wants to make war on generic drugs?

Fighting Malaria: Big Pharma or Better Aid Coordination?
by Pratap ChatterjeeCorpWatch Blog
May 2nd, 2012
Why don’t drug companies invest enough money in treating malaria and tuberculosis? A recent study published in the Lancet magazine estimates that 1,238,000 people died from malaria in 2010. Surely a wonder drug that stops these diseases would be wildly profitable?